The American Society of Hematology (#ASH18) annual meeting is has come to an end. Monday has been traditionally known as “Myeloma Madness Monday.” This year was no different. Oral sessions included topics on the combination therapies, #CAR-T and #BiTE (Bispecific T-cell Engager) therapy. Other potential new agents in #myeloma, like venetoclax, selinexor and isatuximab, were […]